On June 10, 2026, CanSino Biologics Inc. ("CanSinoBIO" or the "Company"; SSE: 688185.SH, HKEX: 06185.HK) successfully held its 2025 Annual General Meeting (AGM).

CanSinoBIO Holds 2025 Annual General Meeting of Shareholders

Dr. Xuefeng Yu, Chairman and Chief Executive Officer of CanSinoBIO, attended the meeting together with all members of the Board of Directors and senior management. The Company engaged in constructive discussions with shareholders on topics including business performance, strategic priorities, and future development plans.

During the AGM, shareholders reviewed and approved 15 resolutions, including the 2025 Report of the Board of Directors, the 2025 Annual Report and its Summary, and the 2025 Profit Distribution Plan. Shareholders also received the 2025 Independent Directors' Performance Report and the 2026 Senior Management Compensation Plan. The meeting adopted a hybrid approach combining on-site and online voting, and all resolutions were duly approved by shareholders and their proxies.

Shareholders and their proxies actively shared insights and suggestions regarding the Company's R&D activities, pipeline progress, commercialization strategy, and international development. The management team carefully considered shareholder feedback and engaged in open and constructive dialogue, providing detailed responses to relevant questions. These exchanges further enhanced investors' understanding of the Company's strategic priorities, operating performance, and long-term value creation potential.

Over the past year, supported by its continuously strengthening R&D and industrialization capabilities, the Company advanced the development of key pipeline assets and technology platforms while dedicated to building a comprehensive life-course immunization strategy. By delivering high-quality products and maintaining a reliable supply network, CanSinoBIO continued to address public health needs. At the same time, the Company further expanded its presence in both domestic and international markets, strengthening its core competitiveness and long-term sustainability. As a result, the Company achieved a significant improvement in profitability, recording positive net profit attributable to shareholders of the parent company in 2025.

As an innovative vaccine company listed on both the Shanghai and Hong Kong stock exchanges, CanSinoBIO places great importance on shareholder rights protection and investor relations management. The Company continues to enhance its corporate governance framework, strengthen compliance and operational excellence, and improve the quality and transparency of information disclosure, striving to create sustainable value for both the Company and its shareholders.

Looking ahead, CanSinoBIO will continue to strengthen its R&D capabilities and operational excellence, further enhance its core competitiveness, and deliver greater value to shareholders and investors through innovative products and sustainable growth, while contributing to global public health with solutions developed in China.

Disclaimer:

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.